Loading...

ELDN ELEDON PHARMACEUTICALS INC Management Changes 8-K Filing

LDN

LDN

ELEDON PHARMACEUTICALS INC

(ELDN)

2024 8-K

Financial Announcement

Stock Exchange Agreement

Quarterly Financial Report

Stock Offering Announced

Financial Update

Financial Restatement Notice

Clinical Trials

Financial Statements

Financial Results

CEO Agreement Update

Financial Results

Trial Data Release

Stock Sale Agreement

Financial Restatement

Accounting Firm Change

Annual Meeting and Incentiv...

Financial Results Announcement

Private Placement

Financial Results Announcement

Financial Results Announcement

Phase 1b Trial Data Announc...

Appointment of Director

Indemnification Agreement A...

Appointment of Director

Financial Results Announcement

Annual Meeting and Incentiv...

Financial Results Announcement

Private Placement

Financial Results Announcement

Press Release and Investor ...

External Links:

Eledon Pharmaceuticals amended CEO David-Alexandre Gros's employment agreement, adjusting his Performance Bonus structure, which now allows for a bonus of up to $15 million if the company's market value reaches $1.5 billion.

AI Assistant

ELEDON PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.